Volume 14, Issue 4, Pages (April 2013)

Slides:

Advertisements

Similar presentations

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Advertisements

Volume 17, Issue 11, Pages (November 2016)

Volume 14, Issue 12, Pages (November 2013)

Volume 357, Issue 9273, Pages (June 2001)

Volume 17, Issue 12, Pages (December 2016)

Volume 6, Issue 7, Pages (July 2005)

Volume 357, Issue 9257, Pages (March 2001)

Volume 359, Issue 9322, Pages (June 2002)

Volume 12, Issue 11, Pages (October 2011)

Volume 376, Issue 9747, Pages (October 2010)

Volume 18, Issue 7, Pages (July 2017)

Volume 11, Issue 4, Pages (April 2012)

Volume 16, Issue 9, Pages (September 2015)

Volume 15, Issue 6, Pages (May 2014)

Volume 14, Issue 4, Pages (April 2013)

Volume 377, Issue 9779, Pages (May 2011)

Volume 377, Issue 9783, Pages (June 2011)

Volume 373, Issue 9666, Pages (March 2009)

Volume 389, Issue 10076, Pages (April 2017)

Volume 371, Issue 9611, Pages (February 2008)

Volume 13, Issue 3, Pages (March 2012)

Volume 366, Issue 9486, Pages (August 2005)

Volume 12, Issue 2, Pages (February 2011)

Volume 15, Issue 4, Pages (April 2014)

Volume 10, Issue 6, Pages (June 2009)

Volume 15, Issue 4, Pages (April 2014)

Volume 9, Issue 10, Pages (October 2008)

Volume 14, Issue 8, Pages (July 2013)

Volume 18, Issue 7, Pages (July 2017)

Volume 14, Issue 8, Pages (July 2013)

Volume 12, Issue 7, Pages (July 2011)

Volume 15, Issue 6, Pages (May 2014)

Volume 18, Issue 3, Pages (March 2017)

Volume 15, Issue 1, Pages (January 2014)

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild- type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised.

Volume 16, Issue 1, Pages (January 2017)

Volume 6, Issue 6, Pages (June 2005)

Volume 13, Issue 1, Pages (January 2012)

Volume 389, Issue 10073, Pages (March 2017)

Volume 14, Issue 6, Pages (May 2013)

Volume 373, Issue 9666, Pages (March 2009)

Volume 385, Issue 9962, Pages (January 2015)

Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled,

Volume 19, Issue 4, Pages (April 2018)

Volume 15, Issue 8, Pages (July 2014)

Volume 15, Issue 12, Pages (November 2014)

Volume 371, Issue 9625, Pages (May 2008)

Volume 18, Issue 8, Pages (August 2017)

Volume 16, Issue 15, Pages (November 2015)

Volume 15, Issue 6, Pages (May 2014)

Volume 14, Issue 6, Pages (May 2013)

Volume 13, Issue 11, Pages (November 2012)

Volume 16, Issue 15, Pages (November 2015)

Volume 5, Issue 4, Pages (April 2018)

Volume 16, Issue 8, Pages (August 2015)

Volume 17, Issue 8, Pages (August 2016)

Volume 14, Issue 8, Pages (July 2013)

Volume 375, Issue 9714, Pages (February 2010)

Volume 15, Issue 6, Pages (May 2014)

Volume 15, Issue 1, Pages (January 2014)

Volume 15, Issue 8, Pages (July 2014)

Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial Dr David Preiss, PhD, Suzanne M Lloyd,

Volume 11, Issue 3, Pages (March 2010)

Volume 11, Issue 1, Pages (January 2010)

Volume 18, Issue 10, Pages (October 2017)

Volume 376, Issue 9747, Pages (October 2010)

Volume 14, Issue 9, Pages (August 2013)

Volume 20, Issue 5, Pages (May 2019)

Volume 14, Issue 7, Pages (June 2013)

Volume 371, Issue 9611, Pages (February 2008)

Presentation transcript:

Volume 14, Issue 4, Pages 317-326 (April 2013) Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial Dr Somnath Mukherjee, FRCP, Christopher N Hurt, MSc, John Bridgewater, MD, Stephen Falk, MD, Sebastian Cummins, MRCP, Harpreet Wasan, FRCR, Tom Crosby, FRCR, Catherine Jephcott, FRCR, Rajarshi Roy, FRCR, Ganesh Radhakrishna, FRCR, Alec McDonald, MD, Ruby Ray, PhD, George Joseph, MBBS, John Staffurth, MD, Prof Ross A Abrams, MD, Gareth Griffiths, MSc, Prof Tim Maughan, FRCR The Lancet Oncology Volume 14, Issue 4, Pages 317-326 (April 2013) DOI: 10.1016/S1470-2045(13)70021-4 Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile The Lancet Oncology 2013 14, 317-326DOI: (10.1016/S1470-2045(13)70021-4) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 2 Kaplan–Meier estimates of progression-free survival, by treatment group The Lancet Oncology 2013 14, 317-326DOI: (10.1016/S1470-2045(13)70021-4) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 3 Kaplan–Meier estimates of overall survival, by treatment group The Lancet Oncology 2013 14, 317-326DOI: (10.1016/S1470-2045(13)70021-4) Copyright © 2013 Elsevier Ltd Terms and Conditions

Figure 4 Quality of life scores Scores are from the QLQ-C30 questionnaire. Error bars show 95% CIs. The Lancet Oncology 2013 14, 317-326DOI: (10.1016/S1470-2045(13)70021-4) Copyright © 2013 Elsevier Ltd Terms and Conditions